PSIWM
VTGN icon

Paradigm Strategies in Wealth Management’s VistaGen Therapeutics VTGN Stock Holding History

Paradigm Strategies in Wealth Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-33
Closed -$3K – 228
2021
Q2 		$3K Buy
+33
New +$2.44K ﹤0.01% 210

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Paradigm Strategies in Wealth Management's VTGN Position: Q3 2021 in Review

Paradigm Strategies in Wealth Management sold out of VistaGen Therapeutics (VTGN) in Q3 2021, closing a stake of 33 shares — an estimated $3K sold.

Paradigm Strategies in Wealth Management first reported a position in VTGN in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 104 funds tracked by Wall St. Rank hold VTGN as of Q3 2021.

  • Paradigm Strategies in Wealth Management reported no remaining VistaGen Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Paradigm Strategies in Wealth Management sold 33 VistaGen Therapeutics shares in Q3 2021, an estimated $3K.
  • Paradigm Strategies in Wealth Management first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 1 quarter.
  • Paradigm Strategies in Wealth Management's VistaGen Therapeutics position peaked at $3K in Q2 2021.
  • 104 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2021.

Based on Paradigm Strategies in Wealth Management's 13F filing for Q3 2021, filed 15 Oct 2021.